Compare Harley-Davidson Inc (HOG) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harley-Davidson Inc vs Summit Therapeutics Inc — how do they compare? Harley-Davidson Inc trades at $25.93 (market cap $2.78B), while Summit Therapeutics Inc trades at $15.26 (market cap $12.06B). The key difference: Summit Therapeutics Inc is far larger — about 4.3× Harley-Davidson Inc's market cap, and Harley-Davidson Inc pays a 2.75% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HOG | SMMT | |
|---|---|---|
Market Cap | $2.78B | $12.06B |
Sector | Consumer Cyclical | Health |
52-Week High | $31.03 | $26.98 |
52-Week Low | $17.19 | $12.55 |
Enterprise Value | $3.19B | $11.39B |
Dividend Yield | 2.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harley-Davidson (HOG) trades at $26.10, up 0.35% with a bullish technical signal from moving averages. The company reported mixed Q2 2026 results with an EPS beat ($0.75 vs. $0.645 expected) but revenue challenges, while raising full-year guidance. Valuation appears reasonable with P/E of 14.84 and P/S of 0.72, though profitability metrics show pressure with net margin at 4.78%.
The outlook remains cautiously optimistic with analyst consensus at $26.00 target. Key opportunities include North American sales strength and cost-cutting initiatives, while risks involve raw material costs and competitive pressures. Institutional activity shows mixed signals with recent large purchases and sales.
Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.
The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
